Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Jun 17

PMID 35711277

Authors

Linda Petrone

Carla Tortorella

Alessandra Aiello

Chiara Farroni

Serena Ruggieri

Concetta Castilletti

Silvia Meschi

Gilda Cuzzi

Valentina Vanini

Fabrizio Palmieri

Luca Prosperini

Shalom Haggiag

Simona Galgani

Alba Grifoni

Alessandro Sette

Claudio Gasperini

Emanuele Nicastri

Delia Goletti

Affiliations

Soon will be listed here.

Abstract

Objectives: We assessed vaccination-induced antibody and cellular response against spike from the ancestral strain and from the Delta Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) variant in patients with Multiple Sclerosis (MS) treated with disease modifying treatments.

Methods: We enrolled 47 patients with MS and nine controls ("no MS") having completed the vaccination schedule within 4-6 months from the first dose. The Interferon (IFN)-γ-response to spike peptides derived from the ancestral and the Delta SARS-CoV-2 was measured by enzyme-linked immunoassay (ELISA). Anti-Receptor Binding Domain (RBD) IgG were also evaluated.

Results: No significant differences were found comparing the IFN-γ-specific immune response between MS and "no MS" subjects to the ancestral ( = 0.62) or Delta peptide pools ( = 0.68). Nevertheless, a reduced IFN-γ-specific response to the ancestral or to the Delta pools was observed in subjects taking fingolimod or cladribine compared to subjects treated with ocrelizumab or IFN-β. The antibody response was significantly reduced in patients with MS compared to "no MS" subjects ( = 0.0452) mainly in patients taking ocrelizumab or fingolimod.

Conclusions: Cellular responses to Delta SARS-CoV-2 variant remain largely intact in patients with MS. However, the magnitude of these responses depends on the specific therapy.

Citing Articles

COVID-19 and multiple sclerosis: challenges and lessons for patient care.

Prosperini L, Arrambide G, Celius E, Goletti D, Killestein J, Kos D Lancet Reg Health Eur. 2024; 44:100979.

PMID: 39429966 PMC: 11486927. DOI: 10.1016/j.lanepe.2024.100979.

Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination.

Aiello A, Ruggieri S, Navarra A, Tortorella C, Vanini V, Haggiag S Vaccines (Basel). 2024; 12(8).

PMID: 39204049 PMC: 11359508. DOI: 10.3390/vaccines12080926.

Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.

Kister I, Curtin R, Piquet A, Borko T, Pei J, Banbury B Ann Clin Transl Neurol. 2024; 11(7):1750-1764.

PMID: 38713096 PMC: 11251481. DOI: 10.1002/acn3.52081.

Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.

Vita S, DAbramo A, Coppola A, Farroni C, Iori A, Faraglia F Front Oncol. 2024; 14:1290614.

PMID: 38414746 PMC: 10896944. DOI: 10.3389/fonc.2024.1290614.

Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity.

Lineburg K, Crooks P, Raju J, Le Texier L, Khaledi P, Berry K iScience. 2023; 26(12):108474.

PMID: 38077128 PMC: 10698266. DOI: 10.1016/j.isci.2023.108474.

References

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

Ferraccioli G, Gremese E, Goletti D, Petrone L, Cantini F, Ugel S . Immune-Guided Therapy of COVID-19. Cancer Immunol Res. 2022; 10(4):384-402. DOI: 10.1158/2326-6066.CIR-21-0675. View

Salter A, Fox R, Newsome S, Halper J, Li D, Kanellis P . Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021; 78(6):699-708. PMC: 7980147. DOI: 10.1001/jamaneurol.2021.0688. View

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211012835. PMC: 8072850. DOI: 10.1177/17562864211012835. View

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017; 17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2. View

Agrati C, Castilletti C, Goletti D, Meschi S, Sacchi A, Matusali G . Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms. 2021; 9(6). PMC: 8235087. DOI: 10.3390/microorganisms9061315. View

Stampanoni Bassi M, Iezzi E, Centonze D . Multiple sclerosis: Inflammation, autoimmunity and plasticity. Handb Clin Neurol. 2022; 184:457-470. DOI: 10.1016/B978-0-12-819410-2.00024-2. View

Reich D, Lucchinetti C, Calabresi P . Multiple Sclerosis. N Engl J Med. 2018; 378(2):169-180. PMC: 6942519. DOI: 10.1056/NEJMra1401483. View

Sormani M, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L . Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021; 89(4):780-789. PMC: 8013440. DOI: 10.1002/ana.26028. View

10.

Gao Y, Cai C, Grifoni A, Muller T, Niessl J, Olofsson A . Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med. 2022; 28(3):472-476. PMC: 8938268. DOI: 10.1038/s41591-022-01700-x. View

11.

Goletti D, Petrone L, Manissero D, Bertoletti A, Rao S, Ndunda N . The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin Microbiol Infect. 2021; 27(12):1784-1789. PMC: 8272618. DOI: 10.1016/j.cmi.2021.07.005. View

12.

Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S . Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology. 2021; 98(5):e541-e554. PMC: 8826460. DOI: 10.1212/WNL.0000000000013108. View

13.

Gadani S, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith M . Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021; 73:103636. PMC: 8520057. DOI: 10.1016/j.ebiom.2021.103636. View

14.

Petrone L, Petruccioli E, Alonzi T, Vanini V, Cuzzi G, Fard S . In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect. 2021; 82(4):58-66. PMC: 7904476. DOI: 10.1016/j.jinf.2021.02.023. View

15.

Apostolidis S, Kakara M, Painter M, Goel R, Mathew D, Lenzi K . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021; 27(11):1990-2001. PMC: 8604727. DOI: 10.1038/s41591-021-01507-2. View

16.

DAbramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C . Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Infect Dis. 2021; 107:247-250. PMC: 8065233. DOI: 10.1016/j.ijid.2021.04.068. View

17.

Sabatino Jr J, Mittl K, Rowles W, Mcpolin K, Rajan J, Laurie M . Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight. 2022; 7(4). PMC: 8876469. DOI: 10.1172/jci.insight.156978. View

18.

Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf D . Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2021; 78(12):1510-1514. PMC: 8461553. DOI: 10.1001/jamaneurol.2021.3599. View

19.

Tarke A, Coelho C, Zhang Z, Dan J, Yu E, Methot N . SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022; 185(5):847-859.e11. PMC: 8784649. DOI: 10.1016/j.cell.2022.01.015. View

20.

Petrone L, Petruccioli E, Vanini V, Cuzzi G, Fard S, Alonzi T . A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2020; 27(2):286.e7-286.e13. PMC: 7547312. DOI: 10.1016/j.cmi.2020.09.051. View